Professor Anthony Chalmers

  • Chair of Clinical Oncology (Clinical Research Garscube)

telephone: 01413306426
email: Anthony.Chalmers@glasgow.ac.uk

Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, Garscube Estate, Glasgow, G61 1QH

Import to contacts

ORCID iDhttps://orcid.org/0000-0002-1746-7278

Research interests

Glioblastoma is the commonest and most aggressive primary brain tumour and is often refractory to conventional cancer treatments. The ultimate aim of our research group is to improve outcomes for patients with these tumours by overcoming their inherent resistance to radiotherapy and chemotherapy.

Much of our work has focused on the DNA repair protein poly(ADP-ribose) polymerase, commonly known as PARP. Drugs that inhibit PARP increase the sensitivity of tumour cells to radiotherapy and to chemotherapy agents such as temozolomide. We are currently developing a series of clinical trials to test whether PARP inhibitors can be safely and effectively combined with radiotherapy and chemotherapy in patients with glioblastoma.

Current and future work will also investigate the effect of the tumour microenvironment on radiation responses of glioblastoma cells. In order to do this we are developing a novel in vitro cell culture system that recapitulates some of the key features of the glioblastoma microenvironment.

Biography

Research groups

  • Cancer Hallmarks to Novel Therapies
  • Comprehensive Cancer Models
  • Re-imagining Radiotherapy

Publications

List by: Type | Date

Jump to: 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008
Number of items: 104.

2024

Jackson, M. R., Richards, A. R., Oladipupo, A.-B. A., Chahal, S. K., Caragher, S., Chalmers, A. J. and Gomez-Roman, N. (2024) ClonoScreen3D - a novel three-dimensional clonogenic screening platform for identification of radiosensitizers for glioblastoma. International Journal of Radiation Oncology, Biology, Physics, 120(1), pp. 162-177. (doi: 10.1016/j.ijrobp.2024.02.046) (PMID:38493899)

Williamson, A., Houston, P., Paterson, J., Chalmers, A. J. , McLoone, P. , Fullerton, N., Foo, S. Y., James, A. and Nowicki, S. (2024) Dosimetric comparison of hippocampal sparing technologies in patients with low grade glioma. Neuro-Oncology Advances, (doi: 10.1093/noajnl/vdae131) (Early Online Publication)

Lorimer, C., Mills, S., Chalmers, A. , Coombes, I., Thompson, G., Glendenning, J., Radon, M., Jones, C., Williamson, A. and Brock, J. (2024) Baseline total brain volume predicts changes in quality of life and overall survival after cranial radiotherapy in older patients with glioblastoma: Results from the prospective BRITER study. Neuro-Oncology Practice, 11(4), pp. 413-420. (doi: 10.1093/nop/npae019) (PMID:39006523)

Werner, J.-M., Petrescu, G. E.D., Boele, F., Preusser, M., Platten, M., Chalmers, A. J. , Short, S. C. and Piil, K. (2024) Chairing scientific sessions at international Neuro-Oncology meetings: an EANO guide for early-career professionals. Neuro-Oncology Practice, (doi: 10.1093/nop/npae060) (Early Online Publication)

Derby, S. et al. (2024) Concurrent olaparib and radiotherapy in elderly patients with newly diagnosed glioblastoma: the phase I dose escalation PARADIGM trial. International Journal of Radiation Oncology, Biology, Physics, 118(5), pp. 1371-1378. (doi: 10.1016/j.ijrobp.2024.01.011) (PMID:38211641)

Wakeham, K., Cooper, T., Rowbottom, C., Chalmers, A. J. , Price, P., Quinlan, S. and Spencer, K. (2024) Towards world-class radiotherapy in the UK: time for transformation. Lancet Oncology, 25(4), pp. 418-419. (doi: 10.1016/S1470-2045(24)00103-7) (PMID:38408465)

Boele, F. et al. (2024) Inequalities in access to neuro-oncology supportive care and rehabilitation: a survey of healthcare professionals’ perspectives. Neuro-Oncology Practice, (doi: 10.1093/nop/npae023) (Early Online Publication)

Derby, S. et al. (2024) Concurrent olaparib and radiation therapy in older patients with newly diagnosed glioblastoma: the phase 1 dose-escalation PARADIGM trial. International Journal of Radiation Oncology, Biology, Physics, 118(5), pp. 1371-1378. (doi: 10.1016/j.ijrobp.2024.01.011) (PMID:38211641)

Tesson, M., Stevenson, K., Karim, S. A., Nixon, C., Chalmers, A. J. , Sansom, O. J., O'Neill, E., Jones, K. and Morton, J. P. (2024) Targeted irradiation in an autochthonous mouse model of pancreatic cancer. Disease Models and Mechanisms, 17(3), dmm050463. (doi: 10.1242/dmm.050463) (PMID:38421046) (PMCID:PMC10958199)

Derby, S. et al. (2024) Inhibition of ATR opposes glioblastoma invasion through disruption of cytoskeletal networks and integrin internalisation via macropinocytosis. Neuro-Oncology, (doi: 10.1093/neuonc/noad210) (PMID:37936324) (Early Online Publication)

2023

Kouli, O. O., McLoone, P. , Morrison, D., Zaorsky, N. G. and Chalmers, A. J. (2023) Risk of stroke-specific mortality after radiotherapy in patients with primary brain tumours. Clinical and Translational Radiation Oncology, 42, 100658. (doi: 10.1016/j.ctro.2023.100658) (PMID:37502698) (PMCID:PMC10368762)

Verhaegen, F. et al. (2023) Roadmap for precision preclinical x-ray radiation studies. Physics in Medicine and Biology, 68(6), 06RM01. (doi: 10.1088/1361-6560/acaf45) (PMID:36584393)

Grocutt, L., Rutherford, A., Caldwell, D., Wilkinson, C., Chalmers, A.J. , Dempsey, L., Kelly, C. and O'Cathail, S.M. (2023) The impact of COVID-19 on radiotherapy services in Scotland, UK: a population-based study. Clinical Oncology, 35(2), e227-e234. (doi: 10.1016/j.clon.2022.11.018) (PMID:36528474) (PMCID:PMC9708615)

Koessinger, D. et al. (2023) Glioblastoma extracellular vesicles influence glial cell hyaluronic acid deposition to promote invasiveness. Neuro-Oncology Advances, 5(1), vdad067. (doi: 10.1093/noajnl/vdad067) (PMID:37334166) (PMCID:PMC10276538)

2022

O'Cathail, S.M. and Chalmers, A.J. (2022) Integrating novel cancer therapies with radiation - illuminating the tunnel. Clinical Oncology, 35(1), pp. 38-41. (doi: 10.1016/j.clon.2022.10.010) (PMID:36333159)

Falcone, M. et al. (2022) Sensitisation of cancer cells to radiotherapy by serine and glycine starvation. British Journal of Cancer, 127(10), pp. 1773-1786. (doi: 10.1038/s41416-022-01965-6) (PMID:36115879) (PMCID:PMC9643498)

Koessinger, A. L. et al. (2022) Increased apoptotic sensitivity of glioblastoma enables therapeutic targeting by BH3-mimetics. Cell Death and Differentiation, 29(10), pp. 2089-2104. (doi: 10.1038/s41418-022-01001-3) (PMID:35473984) (PMCID:PMC9525582)

McAleavey, P. G., Walls, G. M. and Chalmers, A. J. (2022) Radiotherapy-drug combinations in the treatment of glioblastoma: a brief review. CNS Oncology, 11(2), CNS86. (doi: 10.2217/cns-2021-0015) (PMID:35603818) (PMCID:PMC9134931)

Willers, H., Krause, M., Faivre-Finn, C. and Chalmers, A. (2022) Targeting PARP for chemoradiosensitization: opportunities, challenges, and the road ahead. International Journal of Radiation Oncology, Biology, Physics, 112(2), pp. 265-270. (doi: 10.1016/j.ijrobp.2021.10.142) (PMID:34998527)

Jackson, M. R. et al. (2022) Low-dose lung radiotherapy for COVID-19 lung disease: a preclinical efficacy study in a bleomycin model of pneumonitis. International Journal of Radiation Oncology, Biology, Physics, 112(1), pp. 197-211. (doi: 10.1016/j.ijrobp.2021.08.029) (PMID:34478832) (PMCID:PMC8406661)

Aiyappa-Maudsley, R., Chalmers, A. J. and Parsons, J. L. (2022) Factors affecting the radiation response in glioblastoma. Neuro-Oncology Advances, 4(1), vdac156. (doi: 10.1093/noajnl/vdac156) (PMID:36325371) (PMCID:PMC9617255)

Derby, S. J. , Chalmers, A. J. and Carruthers, R. (2022) Radiotherapy-poly(ADP-ribose) polymerase inhibitor combinations: progress to date. Seminars in Radiation Oncology, 32(1), pp. 15-28. (doi: 10.1016/j.semradonc.2021.09.005) (PMID:34861992)

Gutierrez-Quintana, R. , Walker, D. J. , Williams, K. J., Forster, D. M. and Chalmers, A. J. (2022) Radiation-induced neuroinflammation: a potential protective role for poly(ADP-ribose) polymerase inhibitors? Neuro-Oncology Advances, 4(1), vdab190. (doi: 10.1093/noajnl/vdab190) (PMID:35118383) (PMCID:PMC8807076)

2021

Birch, J. et al. (2021) Inhibition of ATR prevents macropinocytosis driven retraction of neurites and opposes invasion in GBM. Research Square, (doi: 10.21203/rs.3.rs-967109/v1) (PMID:37936324)

Tsim, S. et al. (2021) Serum proteomics and plasma fibulin-3 in differentiation of mesothelioma from asbestos-exposed controls and patients with other pleural diseases. Journal of Thoracic Oncology, 16(10), pp. 1705-1717. (doi: 10.1016/j.jtho.2021.05.018) (PMID:34116230) (PMCID:PMC8514249)

Koessinger, A. L. et al. (2021) Increased apoptotic priming of glioblastoma enables therapeutic targeting by BH3-mimetics. bioRxiv, (doi: 10.1101/2021.06.13.448232)

Nile, D. L., Rae, C. , Walker, D. J. , Canning Waddington, J., Vincent, I. , Burgess, K., Gaze, M. N., Mairs, R. J. and Chalmers, A. J. (2021) Inhibition of glycolysis and mitochondrial respiration promotes radiosensitisation of neuroblastoma and glioma cells. Cancer and Metabolism, 9, 24. (doi: 10.1186/s40170-021-00258-5) (PMID:34011385) (PMCID:PMC8136224)

Chalmers, A.J. and Carruthers, R.D. (2021) Radiobiology summaries: DNA damage and repair. Clinical Oncology, 33(5), pp. 275-278. (doi: 10.1016/j.clon.2020.12.006) (PMID:33341330)

Hanna, C. R. , Robb, K. A. , Blyth, K. G. , Jones, R. J. and Chalmers, A. J. (2021) Clinician attitudes to using low dose radiotherapy to treat COVID-19 lung disease. International Journal of Radiation Oncology, Biology, Physics, 109(4), pp. 886-890. (doi: 10.1016/j.ijrobp.2020.12.003) (PMID:33309910) (PMCID:PMC7726525)

Rulach, R. et al. (2021) An international expert survey on the indications and practice of radical thoracic reirradiation for non-small cell lung cancer. Advances in Radiation Oncology, 6(2), 100653. (doi: 10.1016/j.adro.2021.100653) (PMID:33851065) (PMCID:PMC8022147)

Liu, Q. et al. (2021) Loss of TGFβ signaling increases alternative end-joining DNA repair that sensitizes to genotoxic therapies across cancer types. Science Translational Medicine, 13(580), eabc4465. (doi: 10.1126/scitranslmed.abc4465) (PMID:33568520)

Al-mubarak, H., Vallatos, A. , Gallagher, L., Birch, J. , Chalmers, A.J. and Holmes, W.M. (2021) Evaluating potential of multi-parametric MRI using co-registered histology: Application to a mouse model of glioblastoma. Magnetic resonance imaging, 85, pp. 121-127. (doi: 10.1016/j.mri.2021.10.030) (PMID:34687852)

Hadjiyiannakis, D., Dimitroyannis, D., Eastlake, L., Peedell, C., Tripathi, L., Simcock, R., Vyas, A., Deutsch, E. and Chalmers, A.J. (2021) Personal view: low-dose lung radiotherapy should be evaluated as a treatment for severe COVID-19 lung disease. Clinical Oncology, 33(1), e64-e68. (doi: 10.1016/j.clon.2020.08.003) (PMID:32829986) (PMCID:PMC7427522)

2020

Hanna, C. et al. (2020) Pharmacokinetics, safety and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial. Neuro-Oncology, 22(12), pp. 1840-1850. (doi: 10.1093/neuonc/noaa104) (PMID:32347934) (PMCID:PMC7746945)

Koessinger, A. L., Koessinger, D., Stevenson, K., Cloix, C., Mitchell, L., Nixon, C., Gomez-Roman, N. , Chalmers, A. J. , Norman, J. C. and Tait, S. W.G. (2020) Quantitative in vivo bioluminescence imaging of orthotopic patient-derived glioblastoma xenografts. Scientific Reports, 10, 15361. (doi: 10.1038/s41598-020-72322-x) (PMID:32958777) (PMCID:PMC7506024)

Rae, C. , Fragkoulis, G. I. and Chalmers, A. J. (2020) Cytotoxicity and radiosensitizing activity of the fatty acid synthase inhibitor C75 is enhanced by blocking fatty acid uptake in prostate cancer cells. Advances in Radiation Oncology, 5(5), pp. 944-1005. (doi: 10.1016/j.adro.2020.06.022) (PMID:33083663) (PMCID:PMC7557210)

Litchfield, K. et al. (2020) Representative sequencing: unbiased sampling of solid tumor tissue. Cell Reports, 31(5), 107550. (doi: 10.1016/j.celrep.2020.107550) (PMID:32375028)

Jackson, M. R. , Ashton, M., Koessinger, A. L., Dick, C., Verheij, M. and Chalmers, A. J. (2020) Mesothelioma cells depend on the anti-apoptotic protein Bcl-xL for survival and are sensitized to ionizing radiation by BH3-mimetics. International Journal of Radiation Oncology, Biology, Physics, 106(4), pp. 867-877. (doi: 10.1016/j.ijrobp.2019.11.029) (PMID:31786278)

Gomez-Roman, N. , Chong, M. Y., Chahal, S. K., Caragher, S. P., Jackson, M. R. , Stevenson, K. H., Dongre, S. A. and Chalmers, A. J. (2020) Radiation responses of 2D and 3D glioblastoma cells: a novel, 3D-specific radioprotective role of VEGF/Akt signaling through functional activation of NHEJ. Molecular Cancer Therapeutics, 19(2), pp. 575-589. (doi: 10.1158/1535-7163.MCT-18-1320) (PMID:31672763)

Chalmers, A.J. , Chan, C. and Sebag-Montefiore, D. (2020) CTRad 10 years on: from 10-point plan to top 10 achievements. Clinical Oncology, 32(1), pp. 9-12. (doi: 10.1016/j.clon.2019.09.043) (PMID:31543302)

2019

Beckta, J. M., Bindra, R. S. and Chalmers, A. J. (2019) Targeting DNA repair in gliomas. Current Opinion in Neurology, 32(6), pp. 878-885. (doi: 10.1097/WCO.0000000000000760) (PMID:31592790)

Chong, M. Y., Lorimer, C. F., Mehta, S., Ibrahim, E., Brock, J., McBain, C., McLoone, P. and Chalmers, A. J. (2019) An audit of the management of elderly patients with glioblastoma in the UK: have recent trial results changed treatment? CNS Oncology, 8(4), CNS47. (doi: 10.2217/cns-2019-0017) (PMID:31818127) (PMCID:PMC6974914)

Al-Mubarak, H., Vallatos, A. , Gallagher, L., Birch, J. , Gilmour, L., Foster, J., Chalmers, A.J. and Holmes, W.M. (2019) Stacked in-plane histology for quantitative validation of non-invasive imaging biomarkers: application to an infiltrative brain tumour model. Journal of Neuroscience Methods, 326, 108372. (doi: 10.1016/j.jneumeth.2019.108372) (PMID:31348965)

Venkataramani, V. et al. (2019) Glutamatergic synaptic input to glioma cells drives brain tumour progression. Nature, 573(7775), pp. 532-538. (doi: 10.1038/s41586-019-1564-x) (PMID:31534219)

Palma, D. A. et al. (2019) Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial. BMC Cancer, 19(1), 816. (doi: 10.1186/s12885-019-5977-6) (PMID:31426760) (PMCID:PMC6699121)

Vallatos, A. , Al-Mubarak, H.F.I., Birch, J.L. , Gallagher, L., Mullin, J.M., Gilmour, L., Holmes, W.M. and Chalmers, A.J. (2019) Quantitative histopathologic assessment of perfusion MRI as a marker of glioblastoma cell infiltration in and beyond the peritumoral edema region. Journal of Magnetic Resonance Imaging, 50(2), pp. 529-540. (doi: 10.1002/jmri.26580) (PMID:30569620)

Kokurewicz, K. et al. (2019) Focused very high-energy electron beams as a novel radiotherapy modality for producing high-dose volumetric elements. Scientific Reports, 9, 10837. (doi: 10.1038/s41598-019-46630-w) (PMID:31346184) (PMCID:PMC6658670)

Gomez-Roman, N. and Chalmers, A. J. (2019) Patient-specific 3D-printed glioblastomas. Nature Biomedical Engineering, 3, pp. 498-499. (doi: 10.1038/s41551-019-0379-2) (PMID:31148599)

Gobin, M. et al. (2019) A DNA repair and cell cycle gene expression signature in primary and recurrent glioblastoma: prognostic value and clinical implications. Cancer Research, 79(6), pp. 1226-1238. (doi: 10.1158/0008-5472.CAN-18-2076) (PMID:30674534)

Caragher, S., Chalmers, A. J. and Gomez-Roman, M. (2019) Glioblastoma's next top model: novel culture systems for brain cancer radiotherapy research. Cancers, 11(1), 44. (doi: 10.3390/cancers11010044) (PMID:30621226) (PMCID:PMC6356812)

Rutherford, A., Stevenson, K., Tulk, A. and Chalmers, A. J. (2019) Evaluation of four different small animal radiation plans on tumour and normal tissue dosimetry in a glioblastoma mouse model. British Journal of Radiology, 92(1095), 20180469. (doi: 10.1259/bjr.20180469) (PMID:30362815) (PMCID:PMC6541187)

2018

Birch, J. L. et al. (2018) A novel small-molecule inhibitor of MRCK prevents radiation-driven invasion in glioblastoma. Cancer Research, 78(22), pp. 6509-6522. (doi: 10.1158/0008-5472.CAN-18-1697) (PMID:30279244)

Sharma, R. A. et al. (2018) Clinical development of new drug–radiotherapy combinations. Nature Reviews Clinical Oncology, 13(10), pp. 627-642. (doi: 10.1038/nrclinonc.2016.79) (PMID:27245279)

Carruthers, R. D. et al. (2018) Replication stress drives constitutive activation of the DNA damage response and radioresistance in glioblastoma stem-like cells. Cancer Research, 78(17), pp. 5060-5071. (doi: 10.1158/0008-5472.CAN-18-0569) (PMID:29976574) (PMCID:PMC6128404)

Martinez-Zubiaurre, I., Chalmers, A. J. and Hellevik, T. (2018) Radiation-induced transformation of immunoregulatory networks in the tumor stroma. Frontiers in Immunology, 9, 1679. (doi: 10.3389/fimmu.2018.01679) (PMID:30105016) (PMCID:PMC6077256)

Martin, G. A. , Tsim, S., Kidd, A. C., Foster, J. E., McLoone, P. , Chalmers, A. and Blyth, K. G. (2018) Pre-EDIT: protocol for a randomised feasibility trial of elastance-directed intrapleural catheter or talc pleurodesis (EDIT) in malignant pleural effusion. BMJ Open Respiratory Research, 5(1), e000293. (doi: 10.1136/bmjresp-2018-000293) (PMID:29862030) (PMCID:PMC5976095)

Zmuda, F., Blair, A., Liuzzi, M. C., Malviya, G. , Chalmers, A. J. , Lewis, D., Sutherland, A. and Pimlott, S. L. (2018) An 18F-labeled poly(ADP-ribose) polymerase positron emission tomography imaging agent. Journal of Medicinal Chemistry, 61(9), pp. 4103-4114. (doi: 10.1021/acs.jmedchem.8b00138) (PMID:29630818) (PMCID:PMC6007963)

Gray, E. et al. (2018) Health economic evaluation of a serum-based blood test for brain tumour diagnosis: exploration of two clinical scenarios. BMJ Open, 8(5), e017593. (doi: 10.1136/bmjopen-2017-017593) (PMID:29794088) (PMCID:PMC5988134)

Holmes, W. M. , Vallatos, A. , Gilmour, L. and Chalmers, A. J. (2018) Multiple boli arterial spin labelling for high signal-to-noise rodent brain perfusion imaging. Magnetic Resonance in Medicine, 79(2), pp. 1020-1030. (doi: 10.1002/mrm.26706) (PMID:28516482)

Ashton, M. et al. (2018) SYSTEMS-2: a randomised phase II study of radiotherapy dose escalation for pain control in malignant pleural mesothelioma. Clinical and Translational Radiation Oncology, 8, pp. 45-49. (doi: 10.1016/j.ctro.2017.11.004)

Fulton, B. et al. (2018) PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status. Clinical and Translational Radiation Oncology, 8, pp. 12-16. (doi: 10.1016/j.ctro.2017.11.003)

Thompson, M. K., Poortmans, P., Chalmers, A. J. , Faivre-Finn, C., Hall, E., Huddart, R. A., Lievens, Y., Sebag-Montefiore, D. and Coles, C. E. (2018) Practice-changing radiation therapy trials for the treatment of cancer: where are we 150 years after the birth of Marie Curie? British Journal of Cancer, 119, pp. 389-407. (doi: 10.1038/s41416-018-0201-z) (PMID:30061587) (PMCID:PMC6117262)

2017

Lorimer, C.F., Hanna, C. , Saran, F., Chalmers, A. and Brock, J. (2017) Challenges to treating older glioblastoma patients: the influence of clinical and tumour characteristics on survival outcomes. Clinical Oncology, 29(11), pp. 739-747. (doi: 10.1016/j.clon.2017.05.010) (PMID:28807361)

Ashton, M., O'Rourke, N., Currie, S., Rimner, A. and Chalmers, A. (2017) The role of radical radiotherapy in the management of malignant pleural mesothelioma: a systematic review. Radiotherapy and Oncology, 125(1), pp. 1-12. (doi: 10.1016/j.radonc.2017.08.003) (PMID:28859932)

Bindra, R. S., Chalmers, A. J. , Evans, S. and Dewhirst, M. (2017) GBM radiosensitizers: dead in the water…or just the beginning? Journal of Neuro-Oncology, 134(3), pp. 513-521. (doi: 10.1007/s11060-017-2427-7) (PMID:28762004)

Gomez-Roman, N. , Stevenson, K., Gilmour, L., Hamilton, G. and Chalmers, A. (2017) A novel 3D human glioblastoma cell culture system for modeling drug and radiation responses. Neuro-Oncology, 19(2), pp. 229-241. (doi: 10.1093/neuonc/now164) (PMID:27576873) (PMCID:PMC5463789)

Paterson, C. et al. (2017) Study of diffusion weighted MRI as a predictive biomarker of response during radiotherapy for high and intermediate risk squamous cell cancer of the oropharynx: The MeRInO study. Clinical and Translational Radiation Oncology, 2, pp. 13-18. (doi: 10.1016/j.ctro.2016.12.003)

Carruthers, R. and Chalmers, A. J. (2017) Improving the therapeutic ratio of radiotherapy by targeting the DNA damage response. In: Tofilon, P. J. and Camphausen, K. (eds.) Increasing the Therapeutic Ratio of Radiotherapy. Series: Cancer drug discovery and development. Humana Press: Cham, Switzerland, pp. 1-34. ISBN 9783319408521 (doi: 10.1007/978-3-319-40854-5_1)

2016

Kaur, A. et al. (2016) PP2A inhibitor PME-1 drives kinase inhibitor resistance in glioma cells. Cancer Research, 76(23), pp. 7001-7011. (doi: 10.1158/0008-5472.CAN-16-1134) (PMID:27671680)

Tsim, S. et al. (2016) Diagnostic and prognostic biomarkers in the rational assessment of mesothelioma (DIAPHRAGM) study: protocol of a prospective, multi-centre, observational study. BMJ Open, 6(11), e013324. (doi: 10.1136/bmjopen-2016-013324) (PMID:27884852) (PMCID:PMC5168514)

Harrow, S., Hanna, G.G., Faivre-Finn, C., McDonald, F. and Chalmers, A. (2016) The challenges faced in developing novel drug radiation combinations in non-small cell lung cancer. Clinical Oncology, 28(11), pp. 720-725. (doi: 10.1016/j.clon.2016.08.004) (PMID:27591000)

Lorimer, C. F., Saran, F., Chalmers, A. J. and Brock, J. (2016) Glioblastoma in the elderly - how do we choose who to treat? Journal of Geriatric Oncology, 7(6), pp. 453-456. (doi: 10.1016/j.jgo.2016.07.005) (PMID:27478132)

Yahyanejad, S. et al. (2016) NOTCH blockade combined with radiation therapy and temozolomide prolongs survival of orthotopic glioblastoma. Oncotarget, 7(27), pp. 41251-41264. (doi: 10.18632/oncotarget.9275) (PMID:27183910)

Chalmers, A. J. (2016) Science in focus: combining radiotherapy with inhibitors of the DNA damage response. Clinical Oncology, 28(5), pp. 279-282. (doi: 10.1016/j.clon.2016.01.035) (PMID:26920234)

Gomez-Roman, N. , McGregor, F., Chalmers, A. J. and Plumb, J. (2016) Hypoxia-inducible factor 1 alpha is required for the tumourigenic and aggressive phenotype associated with Rab25 expression in ovarian cancer. Oncotarget, 7, 16. (doi: 10.18632/oncotarget.7998) (PMID:26967059) (PMCID:PMC5008389)

Niyazi, M. et al. (2016) ESTRO-ACROP guideline 'target delineation of glioblastomas'. Radiotherapy and Oncology, 118(1), pp. 35-42. (doi: 10.1016/j.radonc.2015.12.003) (PMID:26777122)

2015

Tardito, S. et al. (2015) Glutamine synthetase activity fuels nucleotide biosynthesis and supports growth of glutamine-restricted glioblastoma. Nature Cell Biology, 17(12), pp. 1556-1568. (doi: 10.1038/ncb3272) (PMID:26595383) (PMCID:PMC4663685)

Zmuda, F., Malviya, G. , Blair, A., Boyd, M., Chalmers, A. J. , Sutherland, A. and Pimlott, S. L. (2015) Synthesis and evaluation of a radioiodinated tracer with specificity for poly(ADP-ribose) polymerase-1 (PARP-1) in vivo. Journal of Medicinal Chemistry, 58(21), pp. 8683-8693. (doi: 10.1021/acs.jmedchem.5b01324) (PMID:26469301)

Ahmed, S., Carruthers, R. , Gilmour, L., Yildirim, S., Watts, C. and Chalmers, A. (2015) Selective inhibition of parallel DNA damage response pathways optimizes radiosensitization of glioblastoma stem-like cells. Cancer Research, 75(20), pp. 4416-4428. (doi: 10.1158/0008-5472.can-14-3790) (PMID:26282173)

Mac Leod, N. et al. (2015) F-18 FDG PET-CT influences target delineation when combined with standard CT-based radiotherapy planning in the palliative setting in malignant pleural mesothelioma; an exploratory study. Reports of Radiotherapy and Oncology, 2(2), e3999. (doi: 10.17795/rro-3999)

Carruthers, R. and Chalmers, A. (2015) Combination of PARP inhibitors with clinical radiotherapy. In: Curtin, N. J. and Sharma, R. A. (eds.) PARP Inhibitors for Cancer Therapy. Series: Cancer drug discovery and development, 5 (83). Springer International Publishing, pp. 533-551. ISBN 9783319141503 (doi: 10.1007/978-3-319-14151-0_23)

MacLeod, N. et al. (2015) Is radiotherapy useful for treating pain in mesothelioma?: a phase II trial. Journal of Thoracic Oncology, 10(6), pp. 944-950. (doi: 10.1097/JTO.0000000000000499) (PMID:25654216)

Ichim, G. et al. (2015) Limited mitochondrial permeabilization causes DNA damage and genomic instability in the absence of cell death. Molecular Cell, 57(5), pp. 860-872. (doi: 10.1016/j.molcel.2015.01.018) (PMID:25702873) (PMCID:PMC4352766)

Meisenberg, C., Gilbert, D. C., Chalmers, A. , Haley, V., Gollins, S., Ward, S. E. and El-Khamisy, S. F. (2015) Clinical and cellular roles for TDP1 and TOP1 in modulating colorectal cancer response to irinotecan. Molecular Cancer Therapeutics, 14(2), pp. 575-585. (doi: 10.1158/1535-7163.MCT-14-0762) (PMID:25522766)

Carruthers, R. , Ahmed, S. U., Strathdee, K., Gomez-Roman, N. , Amoah-Buahin, E., Watts, C. and Chalmers, A. J. (2015) Abrogation of radioresistance in glioblastoma stem-like cells by inhibition of ATM kinase. Molecular Oncology, 9(1), pp. 192-203. (doi: 10.1016/j.molonc.2014.08.003)

Blair, A., Zmuda, F., Malviya, G. , Chalmers, A. J. , Dewar, D. , Pimlott, S. L. and Sutherland, A. (2015) A novel 18F-labelled high affinity agent for PET imaging of the translocator protein. Chemical Science, 6(8), pp. 4772-4777. (doi: 10.1039/C5SC01647A)

2014

Ajaz, M., Jefferies, S., Brazil, L., Watts, C. and Chalmers, A. (2014) Current and investigational drug strategies for glioblastoma. Clinical Oncology, 26(7), pp. 419-430. (doi: 10.1016/j.clon.2014.03.012)

Mannino, M., Gomez-Roman, N. , Hochegger, H. and Chalmers, A. J. (2014) Differential sensitivity of Glioma stem cells to Aurora kinase A inhibitors: implications for stem cell mitosis and centrosome dynamics. Stem Cell Research, 13(1), pp. 135-143. (doi: 10.1016/j.scr.2014.05.001) (PMID:24879067) (PMCID:PMC4085484)

Yahyanejad, S., Granton, P. V., Lieuwes, N. G., Gilmour, L., Dubois, L., Theys, J., Chalmers, A. J. , Verhaegen, F. and Vooijs, M. (2014) Complementary use of bioluminescence imaging and contrast-enhanced micro-computed tomography in an orthotopic brain tumor model. Molecular imaging, 13, pp. 1-8. (PMID:25743108)

Smalley, S., Chalmers, A. J. and Morley, S. J. (2014) mTOR inhibition and levels of the DNA repair protein MGMT in T98G glioblastoma cells. Molecular Cancer, 13(144), (doi: 10.1186/1476-4598-13-144)

2013

Hellevik, T., Pettersen, I., Berg, V., Bruun, J., Bartnes, K., Busund, T.-L., Chalmers, A. , Bremnes,, R. and Martinez-Zubiaurre, I. (2013) Changes in the secretory profile of NSCLC-associated fibroblasts after ablative radiotherapy: potential impact on angiogenesis and tumor growth. Translational Oncology, 6(1), pp. 66-74. (doi: 10.1593/tlo.12349) (PMID:23418618) (PMCID:PMC3573655)

2012

Alagoz, M., Gilbert, D.C., El-Khamisy, S. and Chalmers, A. (2012) DNA repair and resistance to topoisomerase I inhibitors: mechanisms, biomarkers and therapeutic targets. Current Medicinal Chemistry, 19(23), pp. 3874-3885. (doi: 10.2174/092986712802002590)

Ford, E., Catt, S., Chalmers, A. and Fallowfield, L. (2012) Systematic review of supportive care needs in patients with primary malignant brain tumors. Neuro-Oncology, 14(4), pp. 392-404. (doi: 10.1093/neuonc/nor229)

Gilbert, D.C., Chalmers, A.J. and El-Khamisy, S.F. (2012) Topoisomerase I inhibition in colorectal cancer: biomarkers and therapeutic targets. British Journal of Cancer, 106(1), pp. 18-24. (doi: 10.1038/bjc.2011.498)

Hellevik, T. et al. (2012) Cancer-associated fibroblasts from human NSCLC survive ablative doses of radiation but their invasive capacity is reduced. Radiation Oncology, 7(59), (doi: 10.1186/1748-717X-7-59)

2011

Mannino, M. and Chalmers, A. J. (2011) Radioresistance of glioma stem cells: Intrinsic characteristic or property of the 'microenvironment-stem cell unit'? Molecular Oncology, 5(4), pp. 374-386. (doi: 10.1016/j.molonc.2011.05.001)

Catt, S. L., Anderson, J. L., Chalmers, A. J. and Fallowfield, L. J. (2011) A UK-wide survey of follow-up practices for patients with high-grade glioma treated with radical intent. Journal of Evaluation in Clinical Practice, 17(1), pp. 1-6. (doi: 10.1111/j.1365-2753.2009.01292.x)

2010

Chalmers, A. J. , Lakshman, M., Chan, N. and Bristow, R. G. (2010) Poly(ADP-ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets. Seminars in Radiation Oncology, 20(4), pp. 274-281. (doi: 10.1016/j.semradonc.2010.06.001)

Chalmers, A. J. (2010) Overcoming resistance of glioblastoma to conventional cytotoxic therapies by the addition of PARP inhibitors. Anti-Cancer Agents in Medicinal Chemistry, 10(7), pp. 520-533. (doi: 10.2174/187152010793498627)

Löser, D. A., Shibata, A., Shibata, A. K., Woodbine, L. J., Jeggo, P. A. and Chalmers, A. J. (2010) Sensitization to radiation and alkylating agents by inhibitors of poly(ADP-ribose) polymerase is enhanced in cells deficient in DNA double-strand break repair. Molecular Cancer Therapeutics, 9(6), pp. 1775-1787. (doi: 10.1158/1535-7163.MCT-09-1027)

Chalmers, A.J. (2010) Evaluating novel radiation techniques for the treatment of cerebral metastases. British Journal of Radiology, 83(986), pp. 98-100. (doi: 10.1259/bjr/15790337)

2009

Chalmers, A.J. , Ruff, E.M., Martindale, C., Lovegrove, N. and Short, S.C. (2009) Cytotoxic effects of temozolomide and radiation are additive- and schedule-dependent. International Journal of Radiation Oncology, Biology, Physics, 75(5), pp. 1511-1519. (doi: 10.1016/j.ijrobp.2009.07.1703)

Dungey, F.A., Caldecott, K.W. and Chalmers, A.J. (2009) Enhanced radiosensitization of human glioma cells by combining inhibition of poly(ADP-ribose) polymerase with inhibition of heat shock protein 90. Molecular Cancer Therapeutics, 8(8), pp. 2243-2245. (doi: 10.1158/1535-7163.MCT-09-0201)

2008

Dungey, F.A., Löser, D.A. and Chalmers, A.J. (2008) Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-ribose) polymerase: mechanisms and therapeutic potential. International Journal of Radiation Oncology, Biology, Physics, 72(4), pp. 1188-1197. (doi: 10.1016/j.ijrobp.2008.07.031)

This list was generated on Wed Nov 20 13:56:35 2024 GMT.
Jump to: Articles | Book Sections
Number of items: 104.

Articles

Jackson, M. R., Richards, A. R., Oladipupo, A.-B. A., Chahal, S. K., Caragher, S., Chalmers, A. J. and Gomez-Roman, N. (2024) ClonoScreen3D - a novel three-dimensional clonogenic screening platform for identification of radiosensitizers for glioblastoma. International Journal of Radiation Oncology, Biology, Physics, 120(1), pp. 162-177. (doi: 10.1016/j.ijrobp.2024.02.046) (PMID:38493899)

Williamson, A., Houston, P., Paterson, J., Chalmers, A. J. , McLoone, P. , Fullerton, N., Foo, S. Y., James, A. and Nowicki, S. (2024) Dosimetric comparison of hippocampal sparing technologies in patients with low grade glioma. Neuro-Oncology Advances, (doi: 10.1093/noajnl/vdae131) (Early Online Publication)

Lorimer, C., Mills, S., Chalmers, A. , Coombes, I., Thompson, G., Glendenning, J., Radon, M., Jones, C., Williamson, A. and Brock, J. (2024) Baseline total brain volume predicts changes in quality of life and overall survival after cranial radiotherapy in older patients with glioblastoma: Results from the prospective BRITER study. Neuro-Oncology Practice, 11(4), pp. 413-420. (doi: 10.1093/nop/npae019) (PMID:39006523)

Werner, J.-M., Petrescu, G. E.D., Boele, F., Preusser, M., Platten, M., Chalmers, A. J. , Short, S. C. and Piil, K. (2024) Chairing scientific sessions at international Neuro-Oncology meetings: an EANO guide for early-career professionals. Neuro-Oncology Practice, (doi: 10.1093/nop/npae060) (Early Online Publication)

Derby, S. et al. (2024) Concurrent olaparib and radiotherapy in elderly patients with newly diagnosed glioblastoma: the phase I dose escalation PARADIGM trial. International Journal of Radiation Oncology, Biology, Physics, 118(5), pp. 1371-1378. (doi: 10.1016/j.ijrobp.2024.01.011) (PMID:38211641)

Wakeham, K., Cooper, T., Rowbottom, C., Chalmers, A. J. , Price, P., Quinlan, S. and Spencer, K. (2024) Towards world-class radiotherapy in the UK: time for transformation. Lancet Oncology, 25(4), pp. 418-419. (doi: 10.1016/S1470-2045(24)00103-7) (PMID:38408465)

Boele, F. et al. (2024) Inequalities in access to neuro-oncology supportive care and rehabilitation: a survey of healthcare professionals’ perspectives. Neuro-Oncology Practice, (doi: 10.1093/nop/npae023) (Early Online Publication)

Derby, S. et al. (2024) Concurrent olaparib and radiation therapy in older patients with newly diagnosed glioblastoma: the phase 1 dose-escalation PARADIGM trial. International Journal of Radiation Oncology, Biology, Physics, 118(5), pp. 1371-1378. (doi: 10.1016/j.ijrobp.2024.01.011) (PMID:38211641)

Tesson, M., Stevenson, K., Karim, S. A., Nixon, C., Chalmers, A. J. , Sansom, O. J., O'Neill, E., Jones, K. and Morton, J. P. (2024) Targeted irradiation in an autochthonous mouse model of pancreatic cancer. Disease Models and Mechanisms, 17(3), dmm050463. (doi: 10.1242/dmm.050463) (PMID:38421046) (PMCID:PMC10958199)

Derby, S. et al. (2024) Inhibition of ATR opposes glioblastoma invasion through disruption of cytoskeletal networks and integrin internalisation via macropinocytosis. Neuro-Oncology, (doi: 10.1093/neuonc/noad210) (PMID:37936324) (Early Online Publication)

Kouli, O. O., McLoone, P. , Morrison, D., Zaorsky, N. G. and Chalmers, A. J. (2023) Risk of stroke-specific mortality after radiotherapy in patients with primary brain tumours. Clinical and Translational Radiation Oncology, 42, 100658. (doi: 10.1016/j.ctro.2023.100658) (PMID:37502698) (PMCID:PMC10368762)

Verhaegen, F. et al. (2023) Roadmap for precision preclinical x-ray radiation studies. Physics in Medicine and Biology, 68(6), 06RM01. (doi: 10.1088/1361-6560/acaf45) (PMID:36584393)

Grocutt, L., Rutherford, A., Caldwell, D., Wilkinson, C., Chalmers, A.J. , Dempsey, L., Kelly, C. and O'Cathail, S.M. (2023) The impact of COVID-19 on radiotherapy services in Scotland, UK: a population-based study. Clinical Oncology, 35(2), e227-e234. (doi: 10.1016/j.clon.2022.11.018) (PMID:36528474) (PMCID:PMC9708615)

Koessinger, D. et al. (2023) Glioblastoma extracellular vesicles influence glial cell hyaluronic acid deposition to promote invasiveness. Neuro-Oncology Advances, 5(1), vdad067. (doi: 10.1093/noajnl/vdad067) (PMID:37334166) (PMCID:PMC10276538)

O'Cathail, S.M. and Chalmers, A.J. (2022) Integrating novel cancer therapies with radiation - illuminating the tunnel. Clinical Oncology, 35(1), pp. 38-41. (doi: 10.1016/j.clon.2022.10.010) (PMID:36333159)

Falcone, M. et al. (2022) Sensitisation of cancer cells to radiotherapy by serine and glycine starvation. British Journal of Cancer, 127(10), pp. 1773-1786. (doi: 10.1038/s41416-022-01965-6) (PMID:36115879) (PMCID:PMC9643498)

Koessinger, A. L. et al. (2022) Increased apoptotic sensitivity of glioblastoma enables therapeutic targeting by BH3-mimetics. Cell Death and Differentiation, 29(10), pp. 2089-2104. (doi: 10.1038/s41418-022-01001-3) (PMID:35473984) (PMCID:PMC9525582)

McAleavey, P. G., Walls, G. M. and Chalmers, A. J. (2022) Radiotherapy-drug combinations in the treatment of glioblastoma: a brief review. CNS Oncology, 11(2), CNS86. (doi: 10.2217/cns-2021-0015) (PMID:35603818) (PMCID:PMC9134931)

Willers, H., Krause, M., Faivre-Finn, C. and Chalmers, A. (2022) Targeting PARP for chemoradiosensitization: opportunities, challenges, and the road ahead. International Journal of Radiation Oncology, Biology, Physics, 112(2), pp. 265-270. (doi: 10.1016/j.ijrobp.2021.10.142) (PMID:34998527)

Jackson, M. R. et al. (2022) Low-dose lung radiotherapy for COVID-19 lung disease: a preclinical efficacy study in a bleomycin model of pneumonitis. International Journal of Radiation Oncology, Biology, Physics, 112(1), pp. 197-211. (doi: 10.1016/j.ijrobp.2021.08.029) (PMID:34478832) (PMCID:PMC8406661)

Aiyappa-Maudsley, R., Chalmers, A. J. and Parsons, J. L. (2022) Factors affecting the radiation response in glioblastoma. Neuro-Oncology Advances, 4(1), vdac156. (doi: 10.1093/noajnl/vdac156) (PMID:36325371) (PMCID:PMC9617255)

Derby, S. J. , Chalmers, A. J. and Carruthers, R. (2022) Radiotherapy-poly(ADP-ribose) polymerase inhibitor combinations: progress to date. Seminars in Radiation Oncology, 32(1), pp. 15-28. (doi: 10.1016/j.semradonc.2021.09.005) (PMID:34861992)

Gutierrez-Quintana, R. , Walker, D. J. , Williams, K. J., Forster, D. M. and Chalmers, A. J. (2022) Radiation-induced neuroinflammation: a potential protective role for poly(ADP-ribose) polymerase inhibitors? Neuro-Oncology Advances, 4(1), vdab190. (doi: 10.1093/noajnl/vdab190) (PMID:35118383) (PMCID:PMC8807076)

Birch, J. et al. (2021) Inhibition of ATR prevents macropinocytosis driven retraction of neurites and opposes invasion in GBM. Research Square, (doi: 10.21203/rs.3.rs-967109/v1) (PMID:37936324)

Tsim, S. et al. (2021) Serum proteomics and plasma fibulin-3 in differentiation of mesothelioma from asbestos-exposed controls and patients with other pleural diseases. Journal of Thoracic Oncology, 16(10), pp. 1705-1717. (doi: 10.1016/j.jtho.2021.05.018) (PMID:34116230) (PMCID:PMC8514249)

Koessinger, A. L. et al. (2021) Increased apoptotic priming of glioblastoma enables therapeutic targeting by BH3-mimetics. bioRxiv, (doi: 10.1101/2021.06.13.448232)

Nile, D. L., Rae, C. , Walker, D. J. , Canning Waddington, J., Vincent, I. , Burgess, K., Gaze, M. N., Mairs, R. J. and Chalmers, A. J. (2021) Inhibition of glycolysis and mitochondrial respiration promotes radiosensitisation of neuroblastoma and glioma cells. Cancer and Metabolism, 9, 24. (doi: 10.1186/s40170-021-00258-5) (PMID:34011385) (PMCID:PMC8136224)

Chalmers, A.J. and Carruthers, R.D. (2021) Radiobiology summaries: DNA damage and repair. Clinical Oncology, 33(5), pp. 275-278. (doi: 10.1016/j.clon.2020.12.006) (PMID:33341330)

Hanna, C. R. , Robb, K. A. , Blyth, K. G. , Jones, R. J. and Chalmers, A. J. (2021) Clinician attitudes to using low dose radiotherapy to treat COVID-19 lung disease. International Journal of Radiation Oncology, Biology, Physics, 109(4), pp. 886-890. (doi: 10.1016/j.ijrobp.2020.12.003) (PMID:33309910) (PMCID:PMC7726525)

Rulach, R. et al. (2021) An international expert survey on the indications and practice of radical thoracic reirradiation for non-small cell lung cancer. Advances in Radiation Oncology, 6(2), 100653. (doi: 10.1016/j.adro.2021.100653) (PMID:33851065) (PMCID:PMC8022147)

Liu, Q. et al. (2021) Loss of TGFβ signaling increases alternative end-joining DNA repair that sensitizes to genotoxic therapies across cancer types. Science Translational Medicine, 13(580), eabc4465. (doi: 10.1126/scitranslmed.abc4465) (PMID:33568520)

Al-mubarak, H., Vallatos, A. , Gallagher, L., Birch, J. , Chalmers, A.J. and Holmes, W.M. (2021) Evaluating potential of multi-parametric MRI using co-registered histology: Application to a mouse model of glioblastoma. Magnetic resonance imaging, 85, pp. 121-127. (doi: 10.1016/j.mri.2021.10.030) (PMID:34687852)

Hadjiyiannakis, D., Dimitroyannis, D., Eastlake, L., Peedell, C., Tripathi, L., Simcock, R., Vyas, A., Deutsch, E. and Chalmers, A.J. (2021) Personal view: low-dose lung radiotherapy should be evaluated as a treatment for severe COVID-19 lung disease. Clinical Oncology, 33(1), e64-e68. (doi: 10.1016/j.clon.2020.08.003) (PMID:32829986) (PMCID:PMC7427522)

Hanna, C. et al. (2020) Pharmacokinetics, safety and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial. Neuro-Oncology, 22(12), pp. 1840-1850. (doi: 10.1093/neuonc/noaa104) (PMID:32347934) (PMCID:PMC7746945)

Koessinger, A. L., Koessinger, D., Stevenson, K., Cloix, C., Mitchell, L., Nixon, C., Gomez-Roman, N. , Chalmers, A. J. , Norman, J. C. and Tait, S. W.G. (2020) Quantitative in vivo bioluminescence imaging of orthotopic patient-derived glioblastoma xenografts. Scientific Reports, 10, 15361. (doi: 10.1038/s41598-020-72322-x) (PMID:32958777) (PMCID:PMC7506024)

Rae, C. , Fragkoulis, G. I. and Chalmers, A. J. (2020) Cytotoxicity and radiosensitizing activity of the fatty acid synthase inhibitor C75 is enhanced by blocking fatty acid uptake in prostate cancer cells. Advances in Radiation Oncology, 5(5), pp. 944-1005. (doi: 10.1016/j.adro.2020.06.022) (PMID:33083663) (PMCID:PMC7557210)

Litchfield, K. et al. (2020) Representative sequencing: unbiased sampling of solid tumor tissue. Cell Reports, 31(5), 107550. (doi: 10.1016/j.celrep.2020.107550) (PMID:32375028)

Jackson, M. R. , Ashton, M., Koessinger, A. L., Dick, C., Verheij, M. and Chalmers, A. J. (2020) Mesothelioma cells depend on the anti-apoptotic protein Bcl-xL for survival and are sensitized to ionizing radiation by BH3-mimetics. International Journal of Radiation Oncology, Biology, Physics, 106(4), pp. 867-877. (doi: 10.1016/j.ijrobp.2019.11.029) (PMID:31786278)

Gomez-Roman, N. , Chong, M. Y., Chahal, S. K., Caragher, S. P., Jackson, M. R. , Stevenson, K. H., Dongre, S. A. and Chalmers, A. J. (2020) Radiation responses of 2D and 3D glioblastoma cells: a novel, 3D-specific radioprotective role of VEGF/Akt signaling through functional activation of NHEJ. Molecular Cancer Therapeutics, 19(2), pp. 575-589. (doi: 10.1158/1535-7163.MCT-18-1320) (PMID:31672763)

Chalmers, A.J. , Chan, C. and Sebag-Montefiore, D. (2020) CTRad 10 years on: from 10-point plan to top 10 achievements. Clinical Oncology, 32(1), pp. 9-12. (doi: 10.1016/j.clon.2019.09.043) (PMID:31543302)

Beckta, J. M., Bindra, R. S. and Chalmers, A. J. (2019) Targeting DNA repair in gliomas. Current Opinion in Neurology, 32(6), pp. 878-885. (doi: 10.1097/WCO.0000000000000760) (PMID:31592790)

Chong, M. Y., Lorimer, C. F., Mehta, S., Ibrahim, E., Brock, J., McBain, C., McLoone, P. and Chalmers, A. J. (2019) An audit of the management of elderly patients with glioblastoma in the UK: have recent trial results changed treatment? CNS Oncology, 8(4), CNS47. (doi: 10.2217/cns-2019-0017) (PMID:31818127) (PMCID:PMC6974914)

Al-Mubarak, H., Vallatos, A. , Gallagher, L., Birch, J. , Gilmour, L., Foster, J., Chalmers, A.J. and Holmes, W.M. (2019) Stacked in-plane histology for quantitative validation of non-invasive imaging biomarkers: application to an infiltrative brain tumour model. Journal of Neuroscience Methods, 326, 108372. (doi: 10.1016/j.jneumeth.2019.108372) (PMID:31348965)

Venkataramani, V. et al. (2019) Glutamatergic synaptic input to glioma cells drives brain tumour progression. Nature, 573(7775), pp. 532-538. (doi: 10.1038/s41586-019-1564-x) (PMID:31534219)

Palma, D. A. et al. (2019) Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial. BMC Cancer, 19(1), 816. (doi: 10.1186/s12885-019-5977-6) (PMID:31426760) (PMCID:PMC6699121)

Vallatos, A. , Al-Mubarak, H.F.I., Birch, J.L. , Gallagher, L., Mullin, J.M., Gilmour, L., Holmes, W.M. and Chalmers, A.J. (2019) Quantitative histopathologic assessment of perfusion MRI as a marker of glioblastoma cell infiltration in and beyond the peritumoral edema region. Journal of Magnetic Resonance Imaging, 50(2), pp. 529-540. (doi: 10.1002/jmri.26580) (PMID:30569620)

Kokurewicz, K. et al. (2019) Focused very high-energy electron beams as a novel radiotherapy modality for producing high-dose volumetric elements. Scientific Reports, 9, 10837. (doi: 10.1038/s41598-019-46630-w) (PMID:31346184) (PMCID:PMC6658670)

Gomez-Roman, N. and Chalmers, A. J. (2019) Patient-specific 3D-printed glioblastomas. Nature Biomedical Engineering, 3, pp. 498-499. (doi: 10.1038/s41551-019-0379-2) (PMID:31148599)

Gobin, M. et al. (2019) A DNA repair and cell cycle gene expression signature in primary and recurrent glioblastoma: prognostic value and clinical implications. Cancer Research, 79(6), pp. 1226-1238. (doi: 10.1158/0008-5472.CAN-18-2076) (PMID:30674534)

Caragher, S., Chalmers, A. J. and Gomez-Roman, M. (2019) Glioblastoma's next top model: novel culture systems for brain cancer radiotherapy research. Cancers, 11(1), 44. (doi: 10.3390/cancers11010044) (PMID:30621226) (PMCID:PMC6356812)

Rutherford, A., Stevenson, K., Tulk, A. and Chalmers, A. J. (2019) Evaluation of four different small animal radiation plans on tumour and normal tissue dosimetry in a glioblastoma mouse model. British Journal of Radiology, 92(1095), 20180469. (doi: 10.1259/bjr.20180469) (PMID:30362815) (PMCID:PMC6541187)

Birch, J. L. et al. (2018) A novel small-molecule inhibitor of MRCK prevents radiation-driven invasion in glioblastoma. Cancer Research, 78(22), pp. 6509-6522. (doi: 10.1158/0008-5472.CAN-18-1697) (PMID:30279244)

Sharma, R. A. et al. (2018) Clinical development of new drug–radiotherapy combinations. Nature Reviews Clinical Oncology, 13(10), pp. 627-642. (doi: 10.1038/nrclinonc.2016.79) (PMID:27245279)

Carruthers, R. D. et al. (2018) Replication stress drives constitutive activation of the DNA damage response and radioresistance in glioblastoma stem-like cells. Cancer Research, 78(17), pp. 5060-5071. (doi: 10.1158/0008-5472.CAN-18-0569) (PMID:29976574) (PMCID:PMC6128404)

Martinez-Zubiaurre, I., Chalmers, A. J. and Hellevik, T. (2018) Radiation-induced transformation of immunoregulatory networks in the tumor stroma. Frontiers in Immunology, 9, 1679. (doi: 10.3389/fimmu.2018.01679) (PMID:30105016) (PMCID:PMC6077256)

Martin, G. A. , Tsim, S., Kidd, A. C., Foster, J. E., McLoone, P. , Chalmers, A. and Blyth, K. G. (2018) Pre-EDIT: protocol for a randomised feasibility trial of elastance-directed intrapleural catheter or talc pleurodesis (EDIT) in malignant pleural effusion. BMJ Open Respiratory Research, 5(1), e000293. (doi: 10.1136/bmjresp-2018-000293) (PMID:29862030) (PMCID:PMC5976095)

Zmuda, F., Blair, A., Liuzzi, M. C., Malviya, G. , Chalmers, A. J. , Lewis, D., Sutherland, A. and Pimlott, S. L. (2018) An 18F-labeled poly(ADP-ribose) polymerase positron emission tomography imaging agent. Journal of Medicinal Chemistry, 61(9), pp. 4103-4114. (doi: 10.1021/acs.jmedchem.8b00138) (PMID:29630818) (PMCID:PMC6007963)

Gray, E. et al. (2018) Health economic evaluation of a serum-based blood test for brain tumour diagnosis: exploration of two clinical scenarios. BMJ Open, 8(5), e017593. (doi: 10.1136/bmjopen-2017-017593) (PMID:29794088) (PMCID:PMC5988134)

Holmes, W. M. , Vallatos, A. , Gilmour, L. and Chalmers, A. J. (2018) Multiple boli arterial spin labelling for high signal-to-noise rodent brain perfusion imaging. Magnetic Resonance in Medicine, 79(2), pp. 1020-1030. (doi: 10.1002/mrm.26706) (PMID:28516482)

Ashton, M. et al. (2018) SYSTEMS-2: a randomised phase II study of radiotherapy dose escalation for pain control in malignant pleural mesothelioma. Clinical and Translational Radiation Oncology, 8, pp. 45-49. (doi: 10.1016/j.ctro.2017.11.004)

Fulton, B. et al. (2018) PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status. Clinical and Translational Radiation Oncology, 8, pp. 12-16. (doi: 10.1016/j.ctro.2017.11.003)

Thompson, M. K., Poortmans, P., Chalmers, A. J. , Faivre-Finn, C., Hall, E., Huddart, R. A., Lievens, Y., Sebag-Montefiore, D. and Coles, C. E. (2018) Practice-changing radiation therapy trials for the treatment of cancer: where are we 150 years after the birth of Marie Curie? British Journal of Cancer, 119, pp. 389-407. (doi: 10.1038/s41416-018-0201-z) (PMID:30061587) (PMCID:PMC6117262)

Lorimer, C.F., Hanna, C. , Saran, F., Chalmers, A. and Brock, J. (2017) Challenges to treating older glioblastoma patients: the influence of clinical and tumour characteristics on survival outcomes. Clinical Oncology, 29(11), pp. 739-747. (doi: 10.1016/j.clon.2017.05.010) (PMID:28807361)

Ashton, M., O'Rourke, N., Currie, S., Rimner, A. and Chalmers, A. (2017) The role of radical radiotherapy in the management of malignant pleural mesothelioma: a systematic review. Radiotherapy and Oncology, 125(1), pp. 1-12. (doi: 10.1016/j.radonc.2017.08.003) (PMID:28859932)

Bindra, R. S., Chalmers, A. J. , Evans, S. and Dewhirst, M. (2017) GBM radiosensitizers: dead in the water…or just the beginning? Journal of Neuro-Oncology, 134(3), pp. 513-521. (doi: 10.1007/s11060-017-2427-7) (PMID:28762004)

Gomez-Roman, N. , Stevenson, K., Gilmour, L., Hamilton, G. and Chalmers, A. (2017) A novel 3D human glioblastoma cell culture system for modeling drug and radiation responses. Neuro-Oncology, 19(2), pp. 229-241. (doi: 10.1093/neuonc/now164) (PMID:27576873) (PMCID:PMC5463789)

Paterson, C. et al. (2017) Study of diffusion weighted MRI as a predictive biomarker of response during radiotherapy for high and intermediate risk squamous cell cancer of the oropharynx: The MeRInO study. Clinical and Translational Radiation Oncology, 2, pp. 13-18. (doi: 10.1016/j.ctro.2016.12.003)

Kaur, A. et al. (2016) PP2A inhibitor PME-1 drives kinase inhibitor resistance in glioma cells. Cancer Research, 76(23), pp. 7001-7011. (doi: 10.1158/0008-5472.CAN-16-1134) (PMID:27671680)

Tsim, S. et al. (2016) Diagnostic and prognostic biomarkers in the rational assessment of mesothelioma (DIAPHRAGM) study: protocol of a prospective, multi-centre, observational study. BMJ Open, 6(11), e013324. (doi: 10.1136/bmjopen-2016-013324) (PMID:27884852) (PMCID:PMC5168514)

Harrow, S., Hanna, G.G., Faivre-Finn, C., McDonald, F. and Chalmers, A. (2016) The challenges faced in developing novel drug radiation combinations in non-small cell lung cancer. Clinical Oncology, 28(11), pp. 720-725. (doi: 10.1016/j.clon.2016.08.004) (PMID:27591000)

Lorimer, C. F., Saran, F., Chalmers, A. J. and Brock, J. (2016) Glioblastoma in the elderly - how do we choose who to treat? Journal of Geriatric Oncology, 7(6), pp. 453-456. (doi: 10.1016/j.jgo.2016.07.005) (PMID:27478132)

Yahyanejad, S. et al. (2016) NOTCH blockade combined with radiation therapy and temozolomide prolongs survival of orthotopic glioblastoma. Oncotarget, 7(27), pp. 41251-41264. (doi: 10.18632/oncotarget.9275) (PMID:27183910)

Chalmers, A. J. (2016) Science in focus: combining radiotherapy with inhibitors of the DNA damage response. Clinical Oncology, 28(5), pp. 279-282. (doi: 10.1016/j.clon.2016.01.035) (PMID:26920234)

Gomez-Roman, N. , McGregor, F., Chalmers, A. J. and Plumb, J. (2016) Hypoxia-inducible factor 1 alpha is required for the tumourigenic and aggressive phenotype associated with Rab25 expression in ovarian cancer. Oncotarget, 7, 16. (doi: 10.18632/oncotarget.7998) (PMID:26967059) (PMCID:PMC5008389)

Niyazi, M. et al. (2016) ESTRO-ACROP guideline 'target delineation of glioblastomas'. Radiotherapy and Oncology, 118(1), pp. 35-42. (doi: 10.1016/j.radonc.2015.12.003) (PMID:26777122)

Tardito, S. et al. (2015) Glutamine synthetase activity fuels nucleotide biosynthesis and supports growth of glutamine-restricted glioblastoma. Nature Cell Biology, 17(12), pp. 1556-1568. (doi: 10.1038/ncb3272) (PMID:26595383) (PMCID:PMC4663685)

Zmuda, F., Malviya, G. , Blair, A., Boyd, M., Chalmers, A. J. , Sutherland, A. and Pimlott, S. L. (2015) Synthesis and evaluation of a radioiodinated tracer with specificity for poly(ADP-ribose) polymerase-1 (PARP-1) in vivo. Journal of Medicinal Chemistry, 58(21), pp. 8683-8693. (doi: 10.1021/acs.jmedchem.5b01324) (PMID:26469301)

Ahmed, S., Carruthers, R. , Gilmour, L., Yildirim, S., Watts, C. and Chalmers, A. (2015) Selective inhibition of parallel DNA damage response pathways optimizes radiosensitization of glioblastoma stem-like cells. Cancer Research, 75(20), pp. 4416-4428. (doi: 10.1158/0008-5472.can-14-3790) (PMID:26282173)

Mac Leod, N. et al. (2015) F-18 FDG PET-CT influences target delineation when combined with standard CT-based radiotherapy planning in the palliative setting in malignant pleural mesothelioma; an exploratory study. Reports of Radiotherapy and Oncology, 2(2), e3999. (doi: 10.17795/rro-3999)

MacLeod, N. et al. (2015) Is radiotherapy useful for treating pain in mesothelioma?: a phase II trial. Journal of Thoracic Oncology, 10(6), pp. 944-950. (doi: 10.1097/JTO.0000000000000499) (PMID:25654216)

Ichim, G. et al. (2015) Limited mitochondrial permeabilization causes DNA damage and genomic instability in the absence of cell death. Molecular Cell, 57(5), pp. 860-872. (doi: 10.1016/j.molcel.2015.01.018) (PMID:25702873) (PMCID:PMC4352766)

Meisenberg, C., Gilbert, D. C., Chalmers, A. , Haley, V., Gollins, S., Ward, S. E. and El-Khamisy, S. F. (2015) Clinical and cellular roles for TDP1 and TOP1 in modulating colorectal cancer response to irinotecan. Molecular Cancer Therapeutics, 14(2), pp. 575-585. (doi: 10.1158/1535-7163.MCT-14-0762) (PMID:25522766)

Carruthers, R. , Ahmed, S. U., Strathdee, K., Gomez-Roman, N. , Amoah-Buahin, E., Watts, C. and Chalmers, A. J. (2015) Abrogation of radioresistance in glioblastoma stem-like cells by inhibition of ATM kinase. Molecular Oncology, 9(1), pp. 192-203. (doi: 10.1016/j.molonc.2014.08.003)

Blair, A., Zmuda, F., Malviya, G. , Chalmers, A. J. , Dewar, D. , Pimlott, S. L. and Sutherland, A. (2015) A novel 18F-labelled high affinity agent for PET imaging of the translocator protein. Chemical Science, 6(8), pp. 4772-4777. (doi: 10.1039/C5SC01647A)

Ajaz, M., Jefferies, S., Brazil, L., Watts, C. and Chalmers, A. (2014) Current and investigational drug strategies for glioblastoma. Clinical Oncology, 26(7), pp. 419-430. (doi: 10.1016/j.clon.2014.03.012)

Mannino, M., Gomez-Roman, N. , Hochegger, H. and Chalmers, A. J. (2014) Differential sensitivity of Glioma stem cells to Aurora kinase A inhibitors: implications for stem cell mitosis and centrosome dynamics. Stem Cell Research, 13(1), pp. 135-143. (doi: 10.1016/j.scr.2014.05.001) (PMID:24879067) (PMCID:PMC4085484)

Yahyanejad, S., Granton, P. V., Lieuwes, N. G., Gilmour, L., Dubois, L., Theys, J., Chalmers, A. J. , Verhaegen, F. and Vooijs, M. (2014) Complementary use of bioluminescence imaging and contrast-enhanced micro-computed tomography in an orthotopic brain tumor model. Molecular imaging, 13, pp. 1-8. (PMID:25743108)

Smalley, S., Chalmers, A. J. and Morley, S. J. (2014) mTOR inhibition and levels of the DNA repair protein MGMT in T98G glioblastoma cells. Molecular Cancer, 13(144), (doi: 10.1186/1476-4598-13-144)

Hellevik, T., Pettersen, I., Berg, V., Bruun, J., Bartnes, K., Busund, T.-L., Chalmers, A. , Bremnes,, R. and Martinez-Zubiaurre, I. (2013) Changes in the secretory profile of NSCLC-associated fibroblasts after ablative radiotherapy: potential impact on angiogenesis and tumor growth. Translational Oncology, 6(1), pp. 66-74. (doi: 10.1593/tlo.12349) (PMID:23418618) (PMCID:PMC3573655)

Alagoz, M., Gilbert, D.C., El-Khamisy, S. and Chalmers, A. (2012) DNA repair and resistance to topoisomerase I inhibitors: mechanisms, biomarkers and therapeutic targets. Current Medicinal Chemistry, 19(23), pp. 3874-3885. (doi: 10.2174/092986712802002590)

Ford, E., Catt, S., Chalmers, A. and Fallowfield, L. (2012) Systematic review of supportive care needs in patients with primary malignant brain tumors. Neuro-Oncology, 14(4), pp. 392-404. (doi: 10.1093/neuonc/nor229)

Gilbert, D.C., Chalmers, A.J. and El-Khamisy, S.F. (2012) Topoisomerase I inhibition in colorectal cancer: biomarkers and therapeutic targets. British Journal of Cancer, 106(1), pp. 18-24. (doi: 10.1038/bjc.2011.498)

Hellevik, T. et al. (2012) Cancer-associated fibroblasts from human NSCLC survive ablative doses of radiation but their invasive capacity is reduced. Radiation Oncology, 7(59), (doi: 10.1186/1748-717X-7-59)

Mannino, M. and Chalmers, A. J. (2011) Radioresistance of glioma stem cells: Intrinsic characteristic or property of the 'microenvironment-stem cell unit'? Molecular Oncology, 5(4), pp. 374-386. (doi: 10.1016/j.molonc.2011.05.001)

Catt, S. L., Anderson, J. L., Chalmers, A. J. and Fallowfield, L. J. (2011) A UK-wide survey of follow-up practices for patients with high-grade glioma treated with radical intent. Journal of Evaluation in Clinical Practice, 17(1), pp. 1-6. (doi: 10.1111/j.1365-2753.2009.01292.x)

Chalmers, A. J. , Lakshman, M., Chan, N. and Bristow, R. G. (2010) Poly(ADP-ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets. Seminars in Radiation Oncology, 20(4), pp. 274-281. (doi: 10.1016/j.semradonc.2010.06.001)

Chalmers, A. J. (2010) Overcoming resistance of glioblastoma to conventional cytotoxic therapies by the addition of PARP inhibitors. Anti-Cancer Agents in Medicinal Chemistry, 10(7), pp. 520-533. (doi: 10.2174/187152010793498627)

Löser, D. A., Shibata, A., Shibata, A. K., Woodbine, L. J., Jeggo, P. A. and Chalmers, A. J. (2010) Sensitization to radiation and alkylating agents by inhibitors of poly(ADP-ribose) polymerase is enhanced in cells deficient in DNA double-strand break repair. Molecular Cancer Therapeutics, 9(6), pp. 1775-1787. (doi: 10.1158/1535-7163.MCT-09-1027)

Chalmers, A.J. (2010) Evaluating novel radiation techniques for the treatment of cerebral metastases. British Journal of Radiology, 83(986), pp. 98-100. (doi: 10.1259/bjr/15790337)

Chalmers, A.J. , Ruff, E.M., Martindale, C., Lovegrove, N. and Short, S.C. (2009) Cytotoxic effects of temozolomide and radiation are additive- and schedule-dependent. International Journal of Radiation Oncology, Biology, Physics, 75(5), pp. 1511-1519. (doi: 10.1016/j.ijrobp.2009.07.1703)

Dungey, F.A., Caldecott, K.W. and Chalmers, A.J. (2009) Enhanced radiosensitization of human glioma cells by combining inhibition of poly(ADP-ribose) polymerase with inhibition of heat shock protein 90. Molecular Cancer Therapeutics, 8(8), pp. 2243-2245. (doi: 10.1158/1535-7163.MCT-09-0201)

Dungey, F.A., Löser, D.A. and Chalmers, A.J. (2008) Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-ribose) polymerase: mechanisms and therapeutic potential. International Journal of Radiation Oncology, Biology, Physics, 72(4), pp. 1188-1197. (doi: 10.1016/j.ijrobp.2008.07.031)

Book Sections

Carruthers, R. and Chalmers, A. J. (2017) Improving the therapeutic ratio of radiotherapy by targeting the DNA damage response. In: Tofilon, P. J. and Camphausen, K. (eds.) Increasing the Therapeutic Ratio of Radiotherapy. Series: Cancer drug discovery and development. Humana Press: Cham, Switzerland, pp. 1-34. ISBN 9783319408521 (doi: 10.1007/978-3-319-40854-5_1)

Carruthers, R. and Chalmers, A. (2015) Combination of PARP inhibitors with clinical radiotherapy. In: Curtin, N. J. and Sharma, R. A. (eds.) PARP Inhibitors for Cancer Therapy. Series: Cancer drug discovery and development, 5 (83). Springer International Publishing, pp. 533-551. ISBN 9783319141503 (doi: 10.1007/978-3-319-14151-0_23)

This list was generated on Wed Nov 20 13:56:35 2024 GMT.

Grants

Grants and Awards listed are those received whilst working with the University of Glasgow.

  • Edinburgh-Glasgow Brain Tumour Centre of Excellence: Advanced Therapies for Glioblastoma
    Brain Tumour Research
    2024 - 2029
     
  • Investigating BH3-mimetic drugs as radiosensitising agents in solid cancers
    Beatson Institute for Cancer Research
    2024 - 2025
     
  • Translating Cutting-Edge Discovery Science into Patient Benefit
    Medical Research Council
    2023 - 2030
     
  • Investigating Complex Crosstalk in the Pancreatic Cancer Microenvironment
    Medical Research Council
    2023 - 2028
     
  • Tipping the balance: pro-and anti-apoptotic proteins as determinants of radiation resistance in mesothelioma.
    Mesothelioma UK
    2023 - 2024
     
  • ECMC QQR 2023-2028
    Cancer Research UK
    2023 - 2024
     
  • To evaluate the unmet information, needs and materials of cancer patients in relation to their course of radiation therapy treatment/ trials.
    Cancer Research UK
    2023 - 2023
     
  • Understanding and targeting cell death pathways in glioblastoma treated with photodynamic therapy
    Beatson Cancer Charity
    2023 - 2025
     
  • Investigating the radioprotective effects of ATM inhibition on the healthy brain
    Brain Research UK
    2022 - 2024
     
  • Overcoming hypoxia mediated resistance to radiotherapy-PARP inhibitor combinations inglioblastoma.
    Cancer Research UK
    2022 - 2023
     
  • Using ex vivo culture to investigate novel radiotherapy drug combinations in glioblastoma in patient resection specimens
    Royal College of Surgeons of Edinburgh
    2022 - 2023
     
  • Glioblastoma mouse model pharmacokinetics-pharmacodynamics study
    Cancer Research UK
    2022 - 2023
     
  • CRUK Centre Renewal 2021
    Cancer Research UK
    2022 - 2023
     
  • RadNet PPA
    Cancer Research UK
    2022 - 2022
     
  • A randomized Phase II trial of standard versus dose escalated radiotherapy in the treatment of pain in malignant pleural mesothelioma (SYSTEMS 2)
    June Hancock Mesothelioma Research Fund
    2022 - 2023
     
  • Investigating BH3 mimetics as radiosensitising agents in glioblastoma and pancreatic ductal adenocarcinoma
    Cancer Research UK
    2022 - 2022
     
  • Developing better models of the blood-tumour barrier to enhance drug development for glioblastoma
    Office of the Chief Scientific Adviser
    2021 - 2023
     
  • Patterns of Glioblastoma Recurrence after Chemoradiation
    Beatson West of Scotland Cancer Centre
    2021 - 2026
     
  • Reducing neurotoxicity from brain irradiation with FLASH radiation and PARP inhibitors
    Cancer Research UK
    2021 - 2022
     
  • Increasing the susceptibility of neuroblastoma cells to radiotherapy by targeting glycolysis and lipogenesis
    Children with Cancer UK
    2021 - 2024
     
  • The feasibility of using multi-modality imaging in the radiotherapy treatment planning of locally advanced rectal cancer
    The Society of Radiographers
    2020 - 2021
     
  • Glasgow RadNet Centre
    Cancer Research UK
    2019 - 2020
     
  • ECMC supplement
    Chief Scientist Office
    2019 - 2020
     
  • Probing the ability of a novel MRCK inhibitor, BDP-0009066, to prolong survival in a pre-clinical model of Glioblastoma
    Cancer Research Technology
    2018 - 2019
     
  • Assessing the efficacy and safety of a new radiotherapy planning method in lung re-irradiation
    Beatson Cancer Charity
    2018 - 2019
     
  • Radiotherapy-drug combinations technician
    Beatson Cancer Charity
    2018 - 2021
     
  • Combining Akt inhibitor MK-2206 with radiation to improve outcomes for glioblastoma
    Cancer Research UK
    2018 - 2019
     
  • Evaluating the therapeutic potential of PARG inhibition in glioblastoma and elucidating the mechanism(s) of action
    Cancer Research UK
    2018 - 2018
     
  • Investigating the role of the actin-myosin regulatory protein MRCK in promoting radiation induced infiltration by glioblastoma cells
    Medical Research Council
    2017 - 2020
     
  • SYSTEMS 2: A randomized Phase II trial of standard versus does escalated radiotherapy in the treatment of pain in malignant pleural mesothelioma
    The London Community Foundation
    2017 - 2018
     
  • Glasgow ECMC
    Cancer Research UK
    2017 - 2019
     
  • Glasgow ECMC
    Chief Scientist Office
    2017 - 2018
     
  • PRISM - Prediction of Resistance to chemotherapy using Somatic Copy Number Variation in Mesothelioma
    British Lung Foundation
    2017 - 2020
     
  • Pre-clinical evaluation of pan-ERBB inhibition to treat KRAS mutant NSCLC
    British Lung Foundation
    2017 - 2020
     
  • A 3D in vitro glioblastoma cell culture system for the identification and evaluation of novel radiosensitisers reducing rodent xenografts studies
    National Centre for the Replacement of Animals Research
    2017 - 2020
     
  • PET imaging of Poly(ADP-ribose)polymerase-1 in brain tumours
    Beatson Cancer Charity
    2017 - 2018
     
  • Overcoming treatment resistance of GBM by inhibition of Hsp90: preclinical studies with AT13387, radiotherapy and temozolomide. RG.CACL.107025.
    Cancer Research UK
    2016 - 2018
     
  • PARADIGM-2: Olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in newly diagnosed glioblastoma stratified by MGMT status: 2 parallel phase I studies
    Cancer Research UK
    2016 - 2020
     
  • Modulating the p53/mdm2 axis to enhance outcomes of radiotherapy for head & neck cancer: tumour and normal tissue studies in vitro and in vivo
    British Association of Head & Neck Oncologists
    2016 - 2017
     
  • Overcoming treatment resistance by activating cell death in mesothelioma
    British Lung Foundation
    2016 - 2018
     
  • Radiotherapy Research Infrastructure
    Beatson Cancer Charity
    2016 - 2019
     
  • ISSF Catalyst: Integrative polyomics approach to identify metabolomic and genomic signatures of glioma stem cells for therapeutic intervention in glioblastoma
    Wellcome Trust
    2016 - 2016
     
  • PARADIGM-Trans: Sample collection associated with the PARADIGM Trial
    Cancer Research UK
    2015 - 2018
     
  • Scottish Radiotherapy Research Forum
    Cancer Research UK
    2015 - 2016
     
  • SYSTEMS 2: A randomized Phase II trial of standard versus does escalated radiotherapy in the treatment of pain in malignant pleural mesothelioma
    Beatson Cancer Charity
    2015 - 2018
     
  • Overcoming treatment resistance and activating cell death in mesothelioma
    Beatson Cancer Charity
    2015 - 2016
     
  • Identification and validation of novel targets for overcoming radiation resistance of glioblastoma stem cells under normoxia and hypoxia
    Cancer Research UK
    2015 - 2017
     
  • Mitochondrial poisoning as a novel strategy to overcome radiation resistance of glioblastoma
    Chief Scientist Office
    2015 - 2017
     
  • ESTABLISHING INTRAVITAL BRAIN IMAGING IN PRE-CLINICAL MOUSE MODELS
    European Society for Radiation Oncology
    2014 - 2014
     
  • Increasing Radiotherapy responsiveness of mesothelioma by activating tumour specific cell death.
    Netherlands Cancer Institute
    2014 - 2016
     
  • Investigating the potential for synergistic radiosensitisation of bladder cancer by gemcitabine and the PARP inhibitor olaparib
    Cancer Research UK
    2014 - 2015
     
  • New Investigator Committee - Meeting Award 3rd Annual Scientific Meeting of the Scottish Radiotherapy Research Forum
    Cancer Research UK
    2014 - 2014
     
  • SYSTEMS 2: A randomized Phase II trial of standard versus does escalated radiotherapy in the treatment of pain in malignant pleural mesothelioma
    June Hancock Mesothelioma Research Fund
    2014 - 2017
     
  • A Phase I study of Olaparib in Combination with Chemo-Radiation in Locally Advanced Pancreatic Cancer.
    Cancer Research UK
    2014 - 2020
     
  • Radiotherapy-Drug Combinations Technician
    Beatson West of Scotland Cancer Centre
    2014 - 2017
     
  • Developing and testing novel therapies targeting the invasive behaviour of human glioblastoma
    NHS Greater Glasgow and Clyde Endowment Funds
    2014 - 2017
     
  • Developing and testing novel therapies targeting the invasive behaviour of human glioblastoma
    The Brain Tumour Charity
    2014 - 2017
     
  • Development Award: Measurement of Small Molecule Pharmacokinetics in invasive Regions of Glioblastoma
    Cancer Research UK
    2014 - 2016
     
  • Radiosensitisation of Glioblastoma multiforme (GBM) by development of a gold nanoparticle (AuNP) delivery system for siRNA silencing of ataxia telangiectasia mutated (Atm)
    Cancer Research UK
    2014 - 2016
     
  • DNA Damage Response in glioblastoma.
    Beatson West of Scotland Cancer Centre
    2013 - 2014
     
  • An examination of diagnostic and prognostic biomarkers in malignant pleural mesothelioma
    Chief Scientist Office
    2013 - 2018
     
  • Cancer Research UK Clinical Trials Unit - Core Programme Funding
    Cancer Research UK
    2013 - 2018
     
  • Comparative global transcriptome analysis of glioma stem like and bulk cells for identification of therapeutic targets
    Cancer Research UK
    2012 - 2013
     
  • Investigation of [18F]-Fluciclatide as a PET imaging agent for imaging angiogenesis in Glioblastoma
    Cancer Research UK
    2012 - 2013
     
  • Increasing Radiotherapy responsiveness of mesothelioma by activating tumour specific cell death.
    British Lung Foundation
    2012 - 2015
     
  • Experimental Cancer Medicine Centre (ECMC)
    Cancer Research UK
    2012 - 2018
     
  • Experimental Cancer Medicine Centre (ECMC)
    Chief Scientist Office
    2012 - 2017
     
  • Molecular Imaging and Targeted Radionuclide Therapy for Cancer: Synthesis of a Novel Radiolabelled PARP-1 Inhibitor
    Cancer Research UK
    2010 - 2012
     
  • Overcoming treatment resistance in glioblastoma multiforme by tumour specific inhibition of DNA repair
    Medical Research Council
    2010 - 2015
     

CRUK RadNet Glasgow Centre

CRUK RadNet Glasgow Centre

@RadNetCRUKGla